A study to compare the safety and effectiveness of topical ozenoxacin vs mupirocin vs fusidic acid in impetigo contagiosa in pediatric age group.
- Conditions
- Health Condition 1: L010- Impetigo
- Registration Number
- CTRI/2024/03/063414
- Lead Sponsor
- Ranjan Rashmiraj Sahu
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Patients with clinical diagnosis of primary Impetigo.
2. Impetigo of mild( < 6 lesion) to moderare(6 to 20 lesion) variety.
3. Total affected area at baseline not exceeding 100 cm2 or more than 2% of the
BSA.
4. Age between 2 month to 15 years.
5. Skin infection rating score more than equal to four.
6. Parent or legal guardian willing to comply with the protocol.
1.Patient age less than 2 month and more than 15 years.
2.Impetigo of severe( >20 lesions)variety and which warrants systemic therapy.
3.Hypersensitivity to fusidic acid,mupirocin and ozenoxacin.
4.Pre existing eczematous dermatitis with clinical evidence of secondary infection or the presence of a bacterial infection that could not be appropriately treated by a topical antibiotic.
5.use of topical or systemic antibiotic or corticosteroids within one week of baseline.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method